Live In Play

Live In Play®

Updated: 22-Jun-20 11:27 ET

KPTI: Karyopharm Therapeutics announces FDA approval of XPOVIO for the treatment of patients with relapsed or refractory DLBCL (20.43 +1.43)

Karyopharm Therapeutics announced that the FDA has approved oral XPOVIO (selinexor), the company's first-in-class, Selective Inhibitor of Nuclear Export (SINE) compound, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.
This indication was approved based on response rate under the FDA's Accelerated Approval Program. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
XPOVIO will be commercially available immediately in this new indication in the US, and Karyopharm will leverage its existing commercial infrastructure to market this second oncology indication.

Cookie Preferences